Acute lung injury timely associated with the administration of tocilizumab
Abstract
Dear editor,
The interleukin-6 receptor inhibitor tocilizumab has been successfully used to treat various autoimmune diseases and has an acceptable, well-established safety profile...
References
- Kastrati K, Aletaha D, Burmester GR, Chwala E, Dejaco C, Dougados M, et al. A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open 2022; 8: e002359. DOI: https://doi.org/10.1136/rmdopen-2022-002359
- Sugihara K, Wakiya R, Shimada H, Kato M, Kameda T, Nakashima S, et al. Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report. Allergy Asthma Clin Immunol 2021; 17: 90. DOI: https://doi.org/10.1186/s13223-021-00594-7
- Sangüesa Gómez C, Flores Robles BJ, Jara Chinarro B, Espinosa Malpartida M, Barbadillo Mateos C. Acute pneumonitis in a patient with adult-onset disease after toclizumab treatment with good response to anakinra. Reumatol Clin 2016; 12: 345-7. DOI: https://doi.org/10.1016/j.reumae.2015.08.005
- Liu Y, Chen L. Impact of interleukin 6 levels on acute lung injury risk and disease severity in critically ill sepsis patients. World J Clin Cases 2024; 12: 5374-81. DOI: https://doi.org/10.12998/wjcc.v12.i23.5374
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2026 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.